MBT-Candara

 

 

 

Contacts:                                                                                                                                                                                                                 Media:
Gertrude Pfost                                                                                                                                                                                                        Barbara Lindheim
MicroBiome Therapeutics                                                                                                                                                                                    BLL Partners, LLC
(609) 216-1203                                                                                                                                                                                                       (212) 584-2276
gertrudepfost@gmail.com

MICROBIOME THERAPEUTICS’ NM504 FOR IMPROVING BLOOD GLUCOSE REGULATION IS
FIRST MICROBIOME MODULATOR TO RECEIVE U.S. PATENT ALLOWANCE

—Two Published Pilot Clinical Trials Showed that First-in-Class GI Microbiome Modulator NM504
Improved Blood Glucose Regulation in Diabetics and Prediabetics—

—Initial Launch as Dietary Supplement to Help Manage Healthy Blood Glucose Levels Slated for 2017—

New Orleans, LA – October 11, 2016 – MicroBiome Therapeutics (MBT) today reported that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s patent application covering the composition and use of lead microbiome modulator NM504. The patent
allowance covers NM504’s unique combination of ingredients as a human microbiome modulator for improving blood glucose regulation. The allowance includes use of NM504 in diabetic patients and prediabetics at risk of developing diabetes, and covers NM504 delivered in any format, including capsules, tablets, and food-like vehicles such as smoothies and nutrition bars.

MicroBiome Therapeutics (MBT) today reported that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s patent
application covering the composition and use of lead microbiome modulator NM504. The patent allowance covers NM504’s unique combination of ingredients as a human microbiome modulator for improving blood glucose regulation. The allowance includes use of NM504 in diabetic patients and prediabetics at risk of developing diabetes, and covers NM504 delivered in any format, including capsules, tablets, and food-like vehicles such as smoothies and nutrition bars.

In a double-blind, randomized, placebo-controlled clinical study, NM504 shifted the gut microflora of prediabetic and Type 2 diabetes patients in beneficial ways, significantly improving post-meal blood glucose and insulin levels.

NM504 is also covered by an issued 2015 U.S. patent for use in combination with metformin to mitigate the limiting GI side effects often encountered with metformin use. The ability of NM504 to improve tolerance of metformin in Type 2 diabetes was demonstrated in a pilot published clinical study.

MBT Chief Scientific Officer Mark Heiman, PhD, noted, “Countering the worldwide epidemic of obesity and other metabolic disorders requires new approaches to help individuals maintain healthy blood glucose levels and manage their weight. NM504 is the first in a new class of GI microbiome modulators that leverage our growing knowledge of the human microbiome to help restore the GI microbiota diversity and balance that are frequently lost as a result of our contemporary diets and lifestyles. We are very pleased that the U.S. Patent Office has recognized the novelty of this important invention.”

U.S. Patent Application No.:14/238,980, A Human Gastrointestinal Microbiome Modulating Food Supplement for Improving Blood Glucose Regulation, is expected to issue in the coming months.

About MicroBiome Therapeutics
MicroBiome Therapeutics LLC (MBT) is a biotechnology company developing novel approaches to metabolic disorders that aim to maintain good health by altering microbial populations and their environment in the GI tract. MBT’s microbiome modulators are designed to augment the growth of certain beneficial bacterial strains and discourage the growth of others. Lead product NM504 is a unique combination of naturally occurring ingredients that improved post-meal blood glucose levels in a pilot controlled clinical trial in prediabetes and Type 2 diabetes patients. In a second pilot clinical study, NM504 was shown to increase the tolerability and efficacy of the first-line diabetes therapy metformin. MN504 will initially be marketed as a dietary supplement to help individuals maintain healthy blood glucose levels. For more information, visit mbiome.com.